阿托伐他汀联合心达康治疗不稳定型心绞痛的效果及对血清NO、ET-1、VEGF的影响

Efficacy of Atorvastatin Combined with Xindakang in Treatment of Patients with Unstable Angina Pectoris and Its Effects on Serum NO,ET-1 and VEGF

目的探讨阿托伐他汀联合心达康用于不稳定型心绞痛的疗效及对血清一氧化氮(NO)、内皮素-1(ET-1)、血管内皮生长因子(VEGF)的影响。方法选取2015年6月—2016年6月德阳市人民医院收治的不稳定型心绞痛106例,按治疗方法分为对照组和观察组,每组53例。对照组给予阿托伐他汀治疗,观察组在对照组基础上加用心达康治疗。比较2组临床疗效,硝酸甘油用量、心绞痛频率;检测并比较2组血清NO、ET-1、VEGF水平及用药安全性。结果观察组总有效率显著高于对照组(P<0.05)。治疗前,2组硝酸甘油用量、心绞痛频率比较差异无统计学意义(P>0.05);治疗后,2组硝酸甘油用量、心绞痛频率较治疗前降低,且观察组明显低于对照组(P<0.05)。治疗前2组血清NO、ET-1、VEGF比较差异无统计学意义(P>0.05);治疗后2组血清ET-1低于治疗前,且观察组低于对照组(P<0.05);血清NO、VEGF均较治疗前上升,且观察组高于对照组(P<0.05)。2组用药不良反应比较差异无统计学意义(P>0.05)。结论阿托伐他汀联合心达康用于不稳定型心绞痛疗效满意,可提高血清NO、VEGF水平,抑制ET-1水平表达。

Objective To investigate efficacy of Atorvastatin combined with Xindakang in treatlnent of patients with unstable angina pectoris and its effects on serum nitric oxide （NO） , endothelin-1 （ET-1） and vascular endothelial growth factor （VEGF） levels. Methods A total of 106 patients with unstable angina pectoris admitted during June 2015 and June 2016 were divided into control group and observation group （n= 53 for each group） according to different treat- lnent methods. Control group was treated with Atotwastatin, while obsetwation group was added with Xindakang on the basis of treatment for control group. Clinical efficacy, nitroglycerin dosage, angina pectoris fi＇equency, serum NO, ET-1 and VEGF levels and lnedication safety were compared in two groups. Results The total effective rate in observation group was significantly higher than that in control group （P 〈 0.05）. Before treatment, there were no significant differ- ences in nitroglycerin dosage and angina pectoris frequency in two groups （P 〉 0. 05） ; after treatlnent, values of nitro- glycerin dosage and pectoris freciuency were significantly lower than those before treatment in two groups, and the values in observation group were significantly lower than those in control group. Before treatlnent, there were no significant differences in serum NO, ET-1 and VEGF in two groups （P 〉 0. 05） ; after treatlnent, serum ET-1 levels were signifi- cantly lower than those before treatment in two groups, and the level in observation group was significantly lower than that in control group （P 〈0.05） ; while serum NO and VEGF levels were significantly higher than those before treatment in two groups, and the levels in observation group were significantly higher than those in control group （P 〈0.05）. There was no significant difference in incidence rate of adverse reaction in two groups （P 〉 0. 05）. Conclusion Atotwastatin combined with Xindakang in treatment of patients with unstable angina pectoris has good efficacy, and it lnay improve serum NO and VEGF levels and inhibit ET-1 expression.